InvestWiserNewbury Pharmaceuticals AB
NEWBRY · Nasdaq Stockholm · Healthcare
2.22SEK
−0.4%last day
Price as of 2 October 2026
Performance
1 month
−7.9%
1 year
−11.6%
3 years, per year
−16.8%
5 years, per year
–
Largest fall, 3 years
−87.9%
Below the peak now
−82.4%
Volatility, 1 year
138.0%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
2.5
Dividend yield
0.0%
Return on equity
−90.0%
Net margin
−24.2%
Market value
7 m USD
Quality, value and trend
Where Newbury Pharmaceuticals stands against every Nordic stock today. 100 is best.
21
Profitability and a sound balance sheet over time. Better than 21% of Nordic stocks.
7
The price measured against earnings, assets and cash flow. Better than 7% of Nordic stocks.
64
The price development over the past year. Better than 64% of Nordic stocks.
14
Quality, value and trend together. Better than 14% of Nordic stocks.
About Newbury Pharmaceuticals
Newbury Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis